We and others [55,70,174] presented the use of this angiogenic factor as a tool for the assessment of the impending risk for preeclampsia, demonstrating lower concentrations of PlGF in cases when compared to controls as early as at least six weeks prior to the onset of the disease [61]. This evidence concerns the gene PGF and preeclampsia.